BioLineRx (BLRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.4M

Revenue (quarter)

$294,000.00

Revenue growth (year over year)

−3.29%

Gross profit (trailing twelve months)

$1.1M

Gross margin

80.03%

Net income (trailing twelve months)

−$10.1M

Net income (quarter)

−$4.3M

Net income growth (year over year)

−10.13%

Net margin

−728.45%

Return on equity

−41.30%

EPS (trailing twelve months)

—

Book value per share

$3.15

P/E (trailing twelve months)

—

Price to book

0.68

Debt to assets

50.36%

Payout ratio

—

Dividend yield

—

Company profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

• Is BioLineRx (BLRX) profitable?

  No. BioLineRx reported a net loss of $10.1M over the trailing twelve months.

• How much revenue does BioLineRx (BLRX) make?

  BioLineRx generated $1.4M in revenue over the trailing twelve months, down 3.29% year over year.

• How do I buy stock in BioLineRx (BLRX)?

  BLRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.